Growth Metrics

Niagen Bioscience (NAGE) Receivables - Net (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Receivables - Net for 15 consecutive years, with $9.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 25.4% to $9.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.7 million, a 25.4% increase, with the full-year FY2025 number at $9.7 million, up 25.4% from a year prior.
  • Receivables - Net was $9.7 million for Q4 2025 at Niagen Bioscience, up from $8.5 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $9.7 million in Q4 2025 to a low of $2.8 million in Q4 2023.
  • A 5-year average of $6.3 million and a median of $6.3 million in 2022 define the central range for Receivables - Net.
  • Peak YoY movement for Receivables - Net: plummeted 40.68% in 2022, then surged 177.43% in 2024.
  • Niagen Bioscience's Receivables - Net stood at $5.2 million in 2021, then tumbled by 40.68% to $3.1 million in 2022, then dropped by 9.68% to $2.8 million in 2023, then skyrocketed by 177.43% to $7.8 million in 2024, then rose by 25.4% to $9.7 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Receivables - Net are $9.7 million (Q4 2025), $8.5 million (Q3 2025), and $9.7 million (Q2 2025).